PMID- 36042588
OWN - NLM
STAT- MEDLINE
DCOM- 20220901
LR  - 20221115
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 34
DP  - 2022 Aug 26
TI  - Effect of cholesterol-lowering agents on soluble epidermal growth factor receptor 
      level in type 2 diabetes and hypercholesterolemia.
PG  - e30287
LID - 10.1097/MD.0000000000030287 [doi]
LID - e30287
AB  - Soluble epidermal growth factor receptor (sEGFR) levels are elevated in patients 
      with type 2 diabetes mellitus (T2DM) and positively correlate with blood glucose 
      and cholesterol levels. However, how cholesterol-lowering treatment in patients 
      with T2DM affects the sEGFR level is unknown. Therefore, we investigated the 
      change of serum sEGFR after cholesterol-lowering treatment in type 2 diabetic 
      patients with hypercholesterolemia. This study is a non-randomized, prospective 
      observational study. A total of 115 patients were treated in either the 
      rosuvastatin monotherapy group (R group, 5 mg/day, n = 59) or the 
      rosuvastatin/ezetimibe combination therapy group (RE group, 5 mg/10 mg/day, n = 
      56) for 12 weeks. We measured serum levels of lipids and sEGFR using an ELISA kit 
      before and after 12 weeks of treatment in each group. The low-density lipoprotein 
      cholesterol (LDL-C) level was significantly reduced (from 130.27 +/- 27.09 to 
      76.24 +/- 26.82 mg/dL; P < .001) after 12 weeks of treatment and more so in the RE 
      group than in the R group (from 131.68 +/- 28.72 to 87.13 +/- 27.04 mg/dL, P < .001 
      in the R group; from 128.78 +/- 25.58 to 64.75 +/- 21.52 mg/dL, P < .001 in the RE 
      group; R vs RE group, P < .001). The sEGFR level was significantly decreased 
      after 12 weeks of treatment (from 50.34 +/- 13.31 to 45.75 +/- 11.54 ng/mL; P = 
      .007). The RE group only showed a significant reduction in the sEGFR level after 
      treatment (from 50.94 +/- 12.10 to 44.80 +/- 11.36 ng/mL; P = .007). Moreover, the 
      sEGFR level was significantly reduced only when the LDL-C level was significantly 
      reduced (from 50.46 +/- 10.66 to 46.24 +/- 11.86 ng/mL; P = .043). The serum sEGFR 
      level was significantly reduced by cholesterol-lowering treatment with 
      rosuvastatin alone or rosuvastatin/ezetimibe. We suggested that sEGFR may play a 
      significant role in insulin resistance (IR) and inflammation, which are central 
      pathophysiological mechanisms. We confirmed the possibility of using sEGFR as a 
      biomarker to predict a good response to lipid-lowering treatment in type 2 
      diabetes patients with hypercholesterolemia.
CI  - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Lee, Jun Choul
AU  - Lee JC
AD  - Department of Internal Medicine, Eulji University School of Medicine, Daejeon, 
      Republic of Korea.
FAU - Joung, Kyong Hye
AU  - Joung KH
AD  - Department of Internal Medicine, Chungnam National University College of 
      Medicine, Daejeon, South Korea.
AD  - Department of Endocrinology, Chungnam National University Sejong Hospital, 
      Sejong, Republic of Korea.
FAU - Kim, Ji Min
AU  - Kim JM
AD  - Department of Internal Medicine, Chungnam National University College of 
      Medicine, Daejeon, South Korea.
AD  - Department of Endocrinology, Chungnam National University Sejong Hospital, 
      Sejong, Republic of Korea.
FAU - Kang, Seon Mee
AU  - Kang SM
AD  - Department of Internal Medicine, Kangwon National University School of Medicine, 
      Chuncheon, Republic of Korea.
AD  - Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, 
      Republic of Korea.
FAU - Kim, Hyun Jin
AU  - Kim HJ
AD  - Department of Internal Medicine, Chungnam National University College of 
      Medicine, Daejeon, South Korea.
FAU - Ku, Bon Jeong
AU  - Ku BJ
AUID- ORCID: 0000-0002-3414-8949
AD  - Department of Internal Medicine, Chungnam National University College of 
      Medicine, Daejeon, South Korea.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EOR26LQQ24 (Ezetimibe)
SB  - IM
MH  - *Anticholesteremic Agents
MH  - Cholesterol
MH  - Cholesterol, LDL
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Drug Therapy, Combination
MH  - ErbB Receptors/therapeutic use
MH  - Ezetimibe/therapeutic use
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors
MH  - *Hypercholesterolemia/drug therapy
MH  - Rosuvastatin Calcium/therapeutic use
MH  - Treatment Outcome
PMC - PMC9410686
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2022/09/01 06:00
MHDA- 2022/09/02 06:00
PMCR- 2022/08/26
CRDT- 2022/08/31 01:11
PHST- 2022/08/31 01:11 [entrez]
PHST- 2022/09/01 06:00 [pubmed]
PHST- 2022/09/02 06:00 [medline]
PHST- 2022/08/26 00:00 [pmc-release]
AID - 00005792-202208260-00007 [pii]
AID - 10.1097/MD.0000000000030287 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Aug 26;101(34):e30287. doi: 
      10.1097/MD.0000000000030287.